Roche receives FDA approval for cobas HPV test for use on the cobas 6800/8800 Systems to identify women at risk for cervical cancer

More than 99 percent of cervical cancers are caused by persistent high-risk HPV infection1 Cervical cancer is nearly 100 percent preventable with proper HPV vaccination, screening and treatment; expanding access helps reach more women2,3 cobas 6800/8800 Systems deliver full automation, helping laboratories meet the throughput and efficiencies that high-volume, HPV DNA screening programs require              Basel,... Read more

PerkinElmer Launches Solutions to Streamline Analysis for Labs in Pharmaceuticals, Semiconductors, Biomonitoring, Food and Materials

Multi-Quadrupole ICP-MS, FT-IR and automation innovations provide testing and research performance, flexibility and ease of use WALTHAM, Mass. – April 15, 2020 – PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today expanded its analysis and automation portfolio for quality, safety and content testing. Geared for pharmaceutical, semiconductor, biomonitoring, food, materials... Read more

SCIEX and Intabio Collaborate to Accelerate Biopharma Drug Development

Collaboration on Novel iCIEF-MS Platform speeds up critical decisions and streamlines approaches in biopharma environment April 08, 2020 Framingham, MA and Newark, CA — SCIEX, a global leader in life science analytical technologies, and Intabio, a developer of innovative instrumentation systems for biotherapeutic precision analysis and quality assessment, announced a collaboration to couple Intabio’s Blaze™ system with... Read more

Unchained Labs jumps into gene therapy and vaccines with new AAV stability application!

April 1, 2020 – Pleasanton, CA – Unchained Labs, the life sciences company that’s all about getting biologics researchers the right tool for the job, launched its new AAV stability application on the Uncle platform today. Uncle is already the gold standard for measuring protein stability and, with this new application, jumps in to support researchers in pursuit... Read more

Danaher Completes Acquisition Of The Biopharma Business Of General Electric Life Sciences; Business Will Be Called Cytiva

Danaher Completes Acquisition Of The Biopharma Business Of General Electric Life Sciences; Business Will Be Called Cytiva WASHINGTON, March 31, 2020 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (“Danaher”) announced today the completion of its acquisition of the Biopharma business from General Electric Company’s (NYSE: GE) Life Sciences division. As part of Danaher, the business will... Read more

GE Announces Completion of BioPharma Sale to Danaher, Receives $20 Billion Net Cash Proceeds

BOSTON, Mass.—March 31, 2020—GE (NYSE:GE) announced today the completion of the sale of its BioPharma business to Danaher Corporation (NYSE:DHR) (“Danaher”) for approximately $20 billion of net proceeds.  GE Chairman and CEO H. Lawrence Culp, Jr., said, “Completing the sale of BioPharma represents a critical milestone on our multi-year transformation, fortifying our considerable sources to... Read more

Thermo Fisher Scientific Continues Investments to Accelerate Biopharma Commercialization

Thermo Fisher Scientific Continues Investments to Accelerate Biopharma Commercialization Capabilities and capacity now available to help customers of all sizes meet increasing demand for new biologics, cell and gene therapies, and drug products NEEDHAM, Mass., March 23, 2020 /PRNewswire/ — For biopharma companies faced with increasing demand for new biologics, cell and gene therapies, and drug... Read more

Danaher Receives Clearance From U.S. Federal Trade Commission For The Acquisition Of The Biopharma Business Of General Electric Life Sciences

Danaher Receives Clearance From U.S. Federal Trade Commission For The Acquisition Of The Biopharma Business Of General Electric Life Sciences WASHINGTON, March 19, 2020 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (“Danaher”) announced today that the U.S. Federal Trade Commission (the “FTC”) has accepted the proposed consent order in connection with Danaher’s definitive agreement with General... Read more

Roche initiates Phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia

Basel, 19 March 2020- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced  we are working with the Food & Drug Administration (FDA) to initiate a randomised, double-blind, placebo-controlled Phase III clinical trial in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), a part of the US Health and Human Services Office of the... Read more

Roche receives FDA approval for CINtec PLUS Cytology test to aid clinicians in improving cervical cancer prevention

Next-generation cytology test provides additional information for HPV-positive women who may have cervical pre-cancer More sensitive than Pap cytology testing when used as triage test for HPV-positive screening results, helping to improve the detection of cervical pre-cancer The first biomarker-based test specifically approved by the FDA to triage women with HPV-positive / Pap cytology-negative co-testing... Read more